FDA considers adding a dozen peptides to its bulk drug compounding list RAPS FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of FDA Puts BPC 157, TB 500, and 5 Other Peptides Under the Microscope: What Prescribers Need to Know About the 503A Review Lengea The Blacklisting of Peptides BPC 157 FDA's new guidelines on bulk drug compounding Pharmacy & Healthcare Legal Blog